Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

technetium Tc 99m-3PRGD2

A radiopharmaceutical agent comprised of a pegylated arginine-glycine-aspartic acid (RGD) dimer (PRGD2) labeled with technetium Tc 99m, with potential alphaVbeta3 integrin imaging activity when used with single photon emission computed tomography (SPECT). After intravenous administration of technetium Tc 99m-3PRGD2, the RGD moiety binds to alphaVbeta3 integrin on the cell membrane via the cyclic RGD motif. Upon PET imaging, alphaVbeta3 integrin-expressing tumor cells can be visualized and expression levels can be quantified. Compared to other radiolabeled RGD-containing peptides, this agent shows an increased affinity for alphaVbeta3 integrin, enhanced tumor uptake as well as improved pharmacokinetics. AlphaVbeta3 integrin, a member of the integrin receptor family, is overexpressed on certain tumor cells and tumor endothelial cells while minimally or not expressed on healthy, normal cells; this receptor plays a key role in angiogenesis, tumor proliferation and survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:((99m)Tc-3PRGD2)
(99m)Tc-PEG(4)-E[PEG(4)-c(RGDfK)](2)
Abbreviation:99mTc-3PRGD2
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search